Nanomedicines for the Efficient Treatment of Intracellular Bacteria: The “ART” Principle

Hongzhao Qi1*, Peipei Shan1, Yin Wang1, Peifeng Li1, Kun Wang1 and Lijun Yang2*

1Department of Aging Research, Institute of Translational Medicine, The Affiliated Hospital of Qindao University, College of Medicine, Qindao University, Qindao, China, 2Qindao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qindao, China

Infections induced by bacteria at present are a severe threat to public health. Compared with extracellular bacteria, intracellular bacteria are harder to get rid of and readily induce chronic inflammation as well as autoimmune disorders. As the development of new antibiotics becomes more and more difficult, the construction of new antibiotic dosage forms is one of the optimal choices for the elimination of intracellular bacteria, and, to date, various nanomedicines have been exploited. However, current nanomedicines have limited treatment efficiency for intracellular bacteria due to the multiple biological barriers. Here in this short review, we focus on systemically administered nanomedicines and divide the treatment of intracellular bacteria with nanomedicines into three steps: 1) Accumulation at the infection site; 2) Recognition of infected cells; 3) Targeting of intracellular bacteria. Furthermore, we summarize how nanomedicines are elaborately designed to achieve the "ART" principle and discuss the problems of experimental models construction. Through this review, we want to remind that the golden approach for the building of cell and animal experimental models should be established, and nanomedicines should be also endowed with the versatility to follow the “ART” principle, efficiently improving the treatment efficiency of nanomedicines for intracellular bacteria.

Keywords: intracellular bacteria, nanomedicines, accumulation, recognition, targeting

INTRODUCTION

Infections induced by intracellular bacteria pose a formidable challenge to clinical therapy (Kamaruzzaman et al., 2017). These intracellular bacteria can invade into cells and survive in active or static states over extended periods. Under the appropriate conditions, they can quickly replicate inside cells resulting in the relapse of infections. Besides, intracellular bacteria can cause chronic inflammation as well as autoimmune disorders (Kaufmann, 2011). Numerous antibiotics, to date, have been clinically used to treat intracellular bacteria-induced infections, but it is hard to completely eradicate intracellular bacteria (Imbuluzqueta et al., 2011). On the one hand, parts of antibiotics such as penicillin and streptomycin possess high hydrophilicity and have restricted cellular penetration. On the other hand, although some antibiotics can readily diffuse into cells, they show low intracellular retention efficiency (Abed and Couvreur, 2014). Although the application of excessive doses of antibiotics can potentially enhance its intracellular concentration, various side effects and toxicities are often encountered (Qiu et al., 2017). In addition, the activity of antibiotics
may also be influenced by intracellular factors such as pH, redox status, and enzymes (Wright, 2005). Taken together, the effective intracellular concentration of antibiotics is often subtherapeutic, resulting in low efficiency against intracellular bacteria and the development of antibiotic resistance.

To enhance the therapy efficiency of antibiotics for intracellular bacteria as well as avoid potential side effects and toxicities, different nanomedicines that can maintain the activity of drugs have been exploited (Qi et al., 2020a). A variety of drug delivery vehicles, such as polymeric nanoparticles (Anversa Dimer et al., 2020) and gold nanoparticles (Chowdhury et al., 2017), have been used to load and deliver antibiotics to kill intracellular bacteria, while the treatment efficiency of current nanomedicines is rather low. In previous researches, we have developed a series of nanomedicines for the treatment of various diseases (Qi et al., 2016; Qi et al., 2018; Han et al., 2019; Qi et al., 2019; Qi et al., 2020b). Therefore, based on our experience, the optimal nanomedicine should undertake the following three steps for the efficient treatment of intracellular bacteria: 1) Accumulation at the infection site; 2) Recognition of infected cells; 3) Targeting of intracellular bacteria. Nanomedicines that follow this “ART” principle can work like guided missiles to precisely eradicate intracellular bacteria. In this mini-review, we will summarize how nanomedicines are elaborately designed to achieve the “ART” principle, facilitating the exploitation of novel nanomedicines for the efficient treatment of intracellular bacteria. It should be noted that we just discuss nanomedicines which are systemically administered in this mini-review because different administration ways may need nanomedicines with different properties.

**ACCUMULATION AT THE SITE OF INFECTION**

Intracellular bacteria can induce local infections such as skin infections and lung infections (Shima et al., 2016). For the treatment of these infections, nanomedicines have to be accumulated at the site of these infections firstly. The targeting mechanisms of nanomedicines include passive targeting and active targeting. Passive targeting depends on the physicochemical properties of nanomedicines, while active targeting mainly relies on the modification of targeting moieties. Below we will discuss these two aspects in great detail.

**Passive Targeting of Nanomedicines**

It has been reported that capillaries in infection sites are often damaged, and the capillary permeability is positively correlated with the severity of infection (Schiffelers et al., 2001). This physiological characteristic plays a crucial role in nanomedicines localization at the infection sites. Owing to the microvascular permeability, nanomedicines can passively extravasate from blood vessels to the infection sites. In the passive targeting process, besides the physiological characteristics of infection sites, physicochemical properties of nanomedicines such as sizes and zeta potentials also affect the targeting efficiency. For example, Fenaroli et al. have reported that PEGylated liposomes (190 nm) accumulate at infection sites more than PEGylated ones (101 nm), while PEGylated liposomes (703 nm) have a lower accumulation efficiency (Fenaroli et al., 2018). They also prove that PEGylated liposomes (101 nm) have a much longer blood circulation time than non-PEGylated liposomes (101 nm), and their accumulation efficiency at infection sites is significantly higher. Furthermore, to enhance the accumulation efficiency, nanomedicines are often prepared with neutral or negative surface charge, potentially reducing the opsonization and avoiding the quick clearance by the immune system (Xiao et al., 2011). In conclusion, nanomedicines can be endowed with long circulation characteristics by controlling their size and surface properties, and these nanomedicines have higher passive targeting ability to infection sites.

It should be noted that, however, nanomedicines that are readily captured by the immune system can potentially show excellent targeting efficiency to infection sites. As an example, rifampicin-loaded PLGA nanoparticles can be taken up by macrophages, and these macrophages would carry nanoparticles to the infection sites because of their chemotaxis (Fenaroli et al., 2014). Even so, this indirectly passive targeting of nanomedicines is potentially inefficient because macrophages may result in the degradation and inactivation of nanomedicines. The application potentials of indirectly passive targeting need further verification.

Passive targeting of nanomedicines to infection sites is based on the enhanced permeability and retention (EPR) effect similar to that of nanomedicines to tumors (Yang et al., 2019). The vasculatures at the tumor sites and the infection sites are similar, and they are often leaky and have high permeability. But the formation mechanism of the EPR effect may be different because the microenvironment of tumor and infection is different. Despite this, the heterogeneity of the EPR effect both at the tumor sites and infection sites has been widely discussed, and it can reduce the passive targeting efficiency (Fang et al., 2020). To reduce the influence of vascular heterogeneity, nanomedicines with active targeting ability have been exploited.

**Active Targeting of Nanomedicines**

Nanomedicines with active targeting ability are more efficient because they can rely on not only the EPR effect but the targeting moieties that can bind with specific receptors in the infection sites. Nanomedicines for targeting tumor microenvironments have been widely designed, and they have got favorable outcomes in tumor treatments (Kim et al., 2021). Different from tumor microenvironments, infectious microenvironments include both host cells and bacteria, and their formation is acute and temporary (Dong et al., 2019; Zhu et al., 2021). A lot of nanomedicines with active targeting ability to infectious microenvironments, to date, have been exploited to efficiently deliver antibiotics to infectious diseases.

Macrophages in infectious microenvironments are often targeted. Nanomedicines conjugating mannose enable active targeting to macrophages which express mannose receptors on the surface. Cai et al. have proved that photoacoustic agents can be modified with mannose to efficiently accumulate at infection sites (Cai et al., 2018a; Cai et al., 2018b). Besides, some
FIGURE 1 | Schematic illustration on the design, synthesis, and potential mechanism of macrophage-monocyte membrane-encapsulated, antimicrobial-conjugated nanoparticles to kill intracellular bacteria (Li et al., 2020).

FIGURE 2 | The preparation of nanomedicines by fusing the extracellular vesicles membrane derived from S. aureus (EV ghost) over the surface of a nanoparticle (NP) and their therapeutic process (Gao et al., 2019).
antimicrobial peptides can be used as targeting moieties. A recent study reported by Yang et al. shows that gentamicin-loaded mesoporous silica nanoparticles can be labeled with a cationic human antimicrobial peptide fragment ubiquicidin (UBI)_{29-41} to target infection sites actively (Yang et al., 2018). However, the lack of corresponding receptors owing to the heterogeneity of infectious microenvironments may limit the efficiency of a single targeting factor.

Biological membranes which contain a variety of ingredients have been applied to endow nanomedicines with multiple targeting capabilities to infection sites. As shown in Figure 1, Li et al. coat antimicrobial nanoparticles with macrophage membranes and these nanomedicines can be selectively taken up by infected macrophages/monocytes through the combination of surface Toll-like receptors and their electronegativity (Li et al., 2020). Extracellular vesicles have recently been used as drug delivery carriers to treat different diseases (Qi et al., 2021).

**Figure 2** shows that Gao et al. use nanoparticles that are coated with membranes of extracellular vesicles secreted by *Staphylococcus aureus* to deliver antibiotics, and these nanomedicines show significantly higher accumulations in kidney, lung, spleen, and heart bearing metastatic *Staphylococcus aureus* infections than in healthy counterparts (Gao et al., 2019). Furthermore, Bose et al. exploit a kind of apoptotic body-based active-targeting carriers. They use reconstructed apoptotic bodies derived from cancer cells to deliver vancomycin, and the resulting nanomedicines can take advantage of the inherent "eat me" signaling of apoptotic bodies to target infected organs (Bose et al., 2020). The versatility of biological membranes can potentially improve the targeting efficiency of nanomedicines, but the heterogeneity of biological membranes should be seriously considered. For example, membranes with different sizes and shapes may construct nanomedicines with distinct properties. Furthermore, the application of viruses that can target specific bacteria has been also used as a potential targeting approach, especially for pulmonary infections (Subramaniam et al., 2019).

It is worth noted that in *vitro* guidance can also realize the infection targeting of nanomedicines (Yu et al., 2020). As an example, magnetic targeting has been recently introduced to enhance the accumulation of nanomedicines at infection sites (Subbiahdoss et al., 2012; Armenia et al., 2018). Ji et al. utilize the magnetic targeting ability of magnetic nanoparticles to deliver glucose oxidase, efficiently eradicating bacterial/fungi biofilms (Ji et al., 2021). However, in *vitro* guidance is only suitable for detected infections. The combination of active targeting and in *vitro* guidance may further improve the targeting efficiency of nanomedicines.

**RECOGNITION OF INFECTED CELLS**

After accumulation at infection sites, nanomedicines should recognize the infected cells and interact with them, facilitating the delivery of antibiotics to intracellular bacteria. There are many types of cells at the site of infection, and recognizing different types of cells requires different methods.

Phagocytic cells, especially macrophages, are often responsible to engulf and remove bacteria. However, once the killing mechanisms of phagocytic cells are subverted, the engulfed bacteria can remain alive inside these cells (Imbuluzqueta et al., 2011). The recognition of these infected phagocytic cells is relatively easy because nanomedicines are readily captured by these cells similar to bacteria. For example, core-shell nanostructures encapsulating gentamicin based on commercial pluronic could be efficiently taken up by the tissue macrophages, resulting in a significant reduction of viable bacteria in the liver and spleen (Ranjan et al., 2009). Furthermore, nanomedicines can also be modified with phagocytic cell-targeting moieties as we have mentioned above to endow them with active targeting ability, further improving the uptake efficiency of phagocytic cells.

However, various intracellular bacteria, such as *Staphylococcus aureus* and *Salmonella*, can also locate in nonphagocytic cells including epithelial cells, fibroblasts, and hepatocytes. For example, *Mycobacterium tuberculosis* locates in both macrophages and hepatocytes (Barrios-Payán et al., 2012), and *Listeria monocytogenes* can persist in not only macrophages but hepatocytes and enterocytes (Barbuddhe and Chakraborty, 2009). To recognize and target these infected nonphagocytic cells, possible approaches are to increase the blood circulation time of nanomedicines by decreasing the uptake of phagocytic cells. Hyaluronan-based nanoparticles have high biocompatibility, so they can effectively accumulate in the skin to deliver antibiotics to dermis and epidermis cells such as keratinocytes and fibroblasts (Montanari et al., 2020; Zheng et al., 2021). Besides, hyaluronan-based nanoparticles also have active targeting ability because they can bind with CD44 isoforms which are highly expressed in dermis and epidermis cells. Therefore, coupling corresponding targeting moieties to nanomedicines can further improve its targeting efficiency to infected nonphagocytic cells. For example, *Mycobacterium* infected cells show increased uptake of arginine by the mediation of cationic transporters, and arginine-conjugated mesoporous silica nanoparticles can efficiently target *Salmonella* infected macrophages and epithelial cells (Mudakavi et al., 2017).

Recognition of infected cells, in fact, is often difficult. Infected cells do not show obvious differences from normal cells, and that is also the reason why bacteria in infected cells can escape from the immune system. To the best of our knowledge, there are no nanomedicines that can precisely recognize infected cells without targeting normal cells by far. Therefore, the recognition of infected cells needs new mechanisms as well as new methods.

**TARGETING OF INTRACELLULAR BACTERIA**

To date, various antibiotics with excellent *in vitro* activity often show limited *in vivo* therapeutic effects. One of the main reasons is that these antibiotics cannot reach the bacteria-harboring intracellular compartments leading to the low effective concentration (Hao et al., 2021). To enhance the therapeutic effects of antibiotics, therefore, nanomedicines need to target...
intracellular bacteria and release antibiotics to the bacteria-located intracellular compartments (He et al., 2021).

Bacteria may inhabit different intracellular compartments (Fenaroli et al., 2020). For example, Listeria monocytogenes would proliferate in the cytosol of cells, while Listeria pneumoniae colonizes in the endoplasmic reticulum like vacuoles. Salmonella enterica often locates in the late endosomal compartments. Besides, the most studied intracellular bacteria, Mycobacterium tuberculosis, survives in phagosomes. Therefore, targeting these intracellular bacteria needs nanomedicines to locate in corresponding compartments.

In some cases, nanomedicines and bacteria would have the same pathway into cells. For these nanomedicines, they can inherently locate in the same compartments with intracellular bacteria, realizing the passive targeting effect. As an example, nanoparticles of mesoporous iron carboxylate metal-organic framework (nanoMOFs) can be internalized by macrophages, and the internalization pathway is principally phagocytosis. These nanoMOFs can colocalize with intracellular Staphylococcus aureus which locates in the phagosomes of macrophages and deliver two antibiotics to fight them (Li et al., 2019). Shi et al. show that iron oxide nanzymes colocalize with Salmonella Enteritidis in autophagic vacuoles, and can promote the antibacterial effects of autophagic vacuoles by increasing reactive oxygen species levels (Shi et al., 2018). Furthermore, many nanomedicines mainly deliver antibiotics to the endosomes or cytoplasm, while bacteria could reside in different intracellular compartments such as vacuoles, nucleus, Golgi apparatus, and endoplasmic reticulum. These nanomedicines have to target intracellular bacteria by actively entering compartments in which bacteria are located, and they are often modified with targeting moieties (Wang et al., 2021; Yin et al., 2021). Yang et al. immobilize bacteria-targeting peptides on the surface shell of lipid nanoparticles to precisely deliver antibiotics, efficiently eliminating intracellular Staphylococcus aureus (Yang et al., 2018). Singh et al. conjugate sushi peptides which have a strong affinity for lipopolysaccharide (LPS) to gold nanoparticles effectively recognizing intracellular Salmonella typhi (Singh et al., 2017). Besides peptides, other targeting moieties can also be used. For example, Fu et al. report that aptamer-modified quantum dots can recognize intracellular Staphylococcus aureus (Fu et al., 2020). Furthermore, novel nanomedicines are exploited recently. Lehar et al. develop a kind of antibody-antibiotic conjugates to eliminate intracellular Staphylococcus aureus, and these antibody-antibiotic conjugates are superior to free antibiotics (Lehar et al., 2015).

**CONCLUSIONS AND FUTURE PERSPECTIVE**

The development of nanomedicines for bacterial infections has attracted wide attention, while the research on nanomedicines for intracellular bacteria is limited by far. Part of this is because nanomedicines need to overcome multiple physiological barriers to effectively target intracellular bacteria. They have to follow the “ART” principle, sequentially realizing the accumulation at the infection sites, recognition of the infected cells, and targeting the intracellular bacteria. For this purpose, therefore, they must be elaborately decorated according to the properties of targeted bacteria, raising the difficulty of designing nanomedicines. Endowing nanomedicines with the targeting ability to the infection sites is a relatively easy step because there would be obvious abnormalities at the infection sites such as vascular heterogeneity and abnormally high expression of certain receptors. By contrast, the precise recognition of the infected cells is still an arduous challenge. The differences between the infected cells and normal cells are often negligible, and the immune system sometimes fails to detect these differences. The specific cellular markers of the infected cells should be screened by the latest biological tests including proteome analysis and sequencing analysis, facilitating the development of targeting moieties. Furthermore, the targeting of intracellular bacteria often needs nanomedicines to possess the ability to respond to the environment. On the one hand, nanomedicines should escape from their intracellular compartments to bacteria-located compartments through their responsiveness. On the other hand, nanomedicines should responsively release antibiotics to bacteria-located compartments. Therefore, nanomedicines should have versatility including active targeting ability and environmental responsiveness for the follow of the “ART” principle.

The other main reason for limited researches on nanomedicines using to eliminate intracellular bacteria is that the construction methods of experimental models are not perfect. In current researches, cells are often co-cultured with bacteria to simulate the model of intracellular bacterial infection. During this process, bacteria may induce the death of cells, while intracellular bacteria are often symbiotic with cells in reality. Under the circumstances, nanomedicines would face a situation that is completely different from reality. Furthermore, the same is true of the construction of animal models. There is no definitive way to prove that bacteria directly applied to animals are certainly located in the intracellular compartments. We have noted that the construction of the intracellular bacteria-infected animal models is similar to that of routine bacteria-infected animal models in current studies, potentially leading to the false-positive therapy effects of nanomedicines on intracellular bacteria-induced infections. Therefore, the researches on nanomedicines for intracellular bacteria require the golden approach for the building of cell and animal experimental models. In addition, other kinds of drugs should also be exploited, such as nucleic acid drugs (Li et al., 2021; Yang et al., 2021; Zong et al., 2021), for the clearance of intracellular bacteria.

In conclusion, it has been harder to develop new antibiotics recently, and nanomedicines have emerged as one of the optimal choices for infections induced by intracellular bacteria. To further realize the clinical translation of these nanomedicines, however, the golden approach for the building of cell and animal experimental models should be established. Furthermore, nanomedicines should be also endowed with the versatility to follow the “ART” principle. For this purpose, they
should be modified with targeting moieties that could target infection sites, infected cells, and intracellular bacteria respectively.

AUTHOR CONTRIBUTIONS

HQ and LY: conceptualization. HQ and PS: original draft preparation. YW and KW: review and editing. PL: supervision.

REFERENCES

Abed, N., and Couvreur, P. (2014). Nanocarriers for Antibiotics: A Promising Solution to Treat Intracellular Bacterial Infections. *Int. J. Antimicrob. Agents* 43, 485–496. doi:10.1016/j.ijantimicag.2014.02.009

Anversa Dimer, F., de Souza Carvalho-Wodarz, C., Goes, A., Cirsinski, K., Herrmann, J., Schmitt, V., et al. (2020). PLGA Nanocapsules Improve the Delivery of Clarithromycin to Kill Intracellular *Staphylococcus Aureus* and *Mycobacterium Avium*. *Nanomedicine: Nanotechnolog*, 24, 102125. doi:10.1016/j.nano.2020.102125

Armenia, I., Marcone, G. L., Berini, F., Orlandi, V. T., Pirrone, C., Martegani, E., Anversa Dimer, F., de Souza Carvalho-Wodarz, C., Goes, A., Cirnski, K., Cai, Q., Fei, Y., An, H.-W., Zhao, X.-X., Ma, Y., Cong, Y., et al. (2018). Magnetic Nanocjugated Teicoplanin: A Novel Tool for Bacterial Infection Site Targeting. *Front. Microbiol.* 9, 2270. doi:10.3389/fmicb.2018.02270

Barbuddhe, S. B., and Chakraborty, T. (2009). Listeria as an Enteroinvasive Pathogen. *Curr. Top. Microbiol. Immunol.* 337, 173–195. doi:10.1007/978-3-642-01846-6_6

Barrios-Payán, J., Saqui-Salces, M., Jeyanathan, M., Alcántara-Vazquez, A., Castafont-Arreola, M., Rook, G., et al. (2012). Extrapolmonary Locations of *Mycobacterium tuberculosis* DNA during Latent Infection. *J. Infect. Dis.* 206, 1194–1205. doi:10.1093/infdis/jis381

Boe, R. J. C., Tharmalingam, N., García Marques, F. J., Sukumar, U. K., Natarajan, A., Zeng, Y., et al. (2020). Reconstructed Apoptotic Bodies as Targeted “Nano Decoys” to Treat Intracellular Bacterial Infections within Macrophages and Cancer Cells. *ACS Nano* 14, 5818–5835. doi:10.1021/acsnano.0c00921

Cai, Q., Fei, Y., An, H.-W., Zhao, X.-X., Ma, Y., Cong, Y., et al. (2018a). Macrophage-Instructed Intracellular *Staphylococcus aureus* Killing by Targeting Photodynamic Dimers. *ACS Appl. Mater. Inter.* 10, 9197–9202. doi:10.1021/acsami.0c02135

Cai, Q., Fei, Y., Hu, L., Huang, Z., Li, L.-L., and Wang, H. (2018b). Chemotaxis-Instructed Intracellular *Staphylococcus aureus* Infection Detection by a Targeting and Self-Assembly Signal-Enhanced Photacoustic Probe. *Nano Lett.* 18, 6229–6236. doi:10.1021/acs.nanolett.8b02286

Chowdhury, R., Ilyas, H., Ghosh, A., Ali, H., Ghoriai, A., Midya, A., et al. (2017). Multivalent Gold Nanoparticle–Peptide Conjugates for Targeting Intracellular Bacterial Infections. *Nanoscale* 9, 14074–14093. doi:10.1039/c7nr04062h

Dong, X., Zhang, C. Y., Gao, J., and Wang, Z. (2019). Targeting of Macrophage-Instructed Intracellular *Staphylococcus aureus* to *Mycobacterium Abscessus*. *Adv. Therap.* 36, 1800360. doi:10.1002/pptc.201800360

Fang, J., Islam, W., and Maeda, H. (2020). Exploiting the Dynamics of the EPR Environment. *Immunol. Rev.* 204, 1–10. doi:10.1111/1605-0312.12679

Fu, F., Zhang, Y., Li, L., Wang, H., Li, Q., Tao, X., et al. (2020). Intracellular Pathogen Detection Based on Dual-Recognition Units Constructed Fluorescence Resonance Energy Transfer Nanoprobe. *Anal. Chem.* 92, 11462–11468. doi:10.1021/acs.analchem.0c02695

Gao, F., Xu, L., Yang, B., Fan, F., and Yang, L. (2019). Kill the Real with the Fake: Eliminate Intracellular *Staphylococcus aureus* Using Nanoparticle Coated with its Extracellular Vesicle Membrane as Active-Targeting Drug Carrier. *ACS Infect. Dis.* 5, 218–227. doi:10.1021/acsinfecdis.8b00212

Han, L., Liu, C., Qi, H., Zhou, J., Wen, J., Wu, D., et al. (2019). Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. *Adv. Mater.* 31, 1805697. doi:10.1002/adma.201805697

Hao, Y., Zheng, W., Sun, Z., Zhang, D., Sui, K., Shen, P., et al. (2021). Marine Polysaccharide-Based Composite Hydrogels Containing Fucoidan: Preparation, Physicochemical Characterization, and Biocompatible Evaluation. *Int. J. Biol. Macromol.* 183, 1978–1986. doi:10.1016/j.ijbiomac.2021.05.190

He, Y., Zhao, W., Dong, Z., Ji, Y., Li, M., Hao, Y., et al. (2021). A Biodegradable Antibacterial Alginate/Cardioxymethyl Chitosan/Kangelux Sponges for Promoting Blood Coagulation and Full-Thickness Wound Healing. *Int. J. Biol. Macromol.* 167, 182–192. doi:10.1016/j.ijbiomac.2020.11.168

Imbuluqueta, E., Elizondo, E., Gamazo, C., Moreno-Calvo, E., Veciana, J., Ventosa, N., et al. (2011). Novel Bioactive Hydrophobic Gentamicin Carriers for the Treatment of Intracellular Bacterial Infections. *Acta Biomater.* 7, 1599–1608. doi:10.1016/j.actbio.2010.11.031

Ji, Y., Han, Z., Ding, H., Xu, X., Wang, D., Zhu, Y., et al. (2021). Enhanced Eradication of Bacterial/Fungi Biofilms by Glucose Oxidase-Modified Magnetic Nanoparticles as a Potential Treatment for Persistent Endodontic Infections. *ACS Appl. Mater. Inter.* 13, 17289–17299. doi:10.1021/acsami.1c01748

Kamaruzzaman, N. F., Kendall, S., and Good, L. (2017). Targeting the Hard to Reach: Challenges and Novel Strategies in the Treatment of Intracellular Bacterial Infections. *Br. J. Pharmacol.* 174, 2225–2236. doi:10.1111/bph.13664

Kauffmann, S. H. E. (2011). Intracellular Pathogens: Living in an Extreme Environment. *Immunol. Rev.* 240, 5–10. doi:10.1111/j.1605-065X.2010.01001.x

Kim, J., Hong, J., Lee, J., Fakhraei Lahiji, S., and Kim, Y.-H. (2021). Recent Advances in Tumor Microenvironment-Targeted Nanomedicine Delivery Approaches to Overcome Limitations of Immune Checkpoint Blockade-Based Immunotherapy. *J. Controlled Release* 332, 109–126. doi:10.1016/j.jconrel.2021.02.002

Lelah, S. M., Pillow, T., Xu, M., Staben, L., Kajihaara, K. K., Vndlen, R., et al. (2015). Novel Antibody-Antibiotic Conjugate Eliminates Intracellular S. A. Nature 527, 323–328. doi:10.1038/nature16057

Li, X., Semiramoth, N., Hall, S., Tafani, V., Josse, J., Laurent, F., et al. (2019). Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: An Efficient Strategy to Treat Intracellular Infections. *Part. Part. Syst. Charact.* 36, 1800360. doi:10.1002/ppsc.201800360

Li, Y., Yang, Y., Wang, Z., Jiang, S., Meng, Y., Song, X., et al. (2021). Targeting Non-Coding RNAs in Unstable Atherosclerotic Plaques: Mechanism, Regulation, Possibilities, and Limitations. *Int. J. Biol. Sci.* 17, 3413–3427. doi:10.7150/ijbs.62506

Li, X., Liu, Y., Ren, Y., Su, L., Li, A., An, Y., et al. (2020). Coating of a Novel Antimicrobial Nanoparticle with a Macropage Membrane for the Selective Entry into Infected Macrophages and Killing of Intracellular Staphylococci. *Adv. Funct. Mater.* 30, 2004942. doi:10.1002/adfm.202004942

Montanari, E., Mancini, P., Galì, F., Varani, M., Santino, I., Covelli, T., et al. (2020). Biodistribution and Intracellular Localization of Hyaluronan and its

All authors contributed to the manuscript and approved the submitted version.

FUNDING

This work was supported by the National Nature Science Foundation of China (No. 52103170) and the Nature Science Foundation of Shandong Province (No. ZR2019BC020).

Frontiers in Chemistry | www.frontiersin.org 6 October 2021 | Volume 9 | Article 775682
Qi et al. Nanomedicines for Intracellular Bacteria

Subramaniam, S., Thomas, N., Gustafsson, H., and Liu, C. (2016). Development of Arginine Based Nanocarriers for Targeting and Treatment of Intracellular Salmonella. RSC Adv. 7, 7022–7032. doi:10.1039/c6ra27868

Qi, H., Liu, C., Long, L., Ren, Y., Zhang, S., Chang, X., et al. (2016). Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy. ACS Nano 10, 3323–3333. doi:10.1021/acsnano.5b06939

Qi, H., Wang, Y., Fa, S., Yuan, C., and Yang, L. (2021). Extracellular Vesicles as Natural Delivery Carriers Regulate Oxidative Stress under Pathological Conditions. Front. Bioeng. Biotechnol. 9, 810. doi:10.3389/fbioe.2021.752019

Qi, H., Wang, Y., Yuan, X., Li, P., and Yang, L. (2020a). Selective Extracellular Arginine Deprivation by a Single Injection of Cellular Non-Uptake Arginine Deiminase Nanocapsules for Sustained Tumor Inhibition. Nanoscale 12, 24030–24043. doi:10.1039/D0NR06823C

Qi, H., Yang, L., Li, X., Sun, X., Zhao, J., Hou, X., et al. (2019). Systemic Administration of Enzyme-Responsive Growth Factor Nanocapsules for Promoting Bone Repair. Biomater. Sci. 7, 1675–1685. doi:10.1039/C8BM01632A

Qi, H., Yang, L., Li, X., Zhan, Q., Han, D., Zhao, J., et al. (2018). Exosomes Separated Based on the ‘STOP’ Criteria for Tumor-Targeted Drug Delivery. J. Mater. Chem. B 6, 2758–2768. doi:10.1039/C8TB00333F

Qi, H., Yang, L., Shan, P., Zha, S., Ding, H., Xue, S., et al. (2020b). The Stability Maintenance of Protein Drugs in Organic Coatings Based on Nanocaps. Pharmaceutics 12, 115. doi:10.3936/pharmaceutics1200115

Qiu, Y., Hou, Y., Sun, F., Chen, P., Wang, D., Mu, H., et al. (2017). Hyaluronic Acid Conjugation Facilitates Clearance of Intracellular Bacterial Infections by Streptomyacin with Neglectable Nephrotoxicity. Glycobiology 27, 861–867. doi:10.1093/glycob/cwx061

Ranjan, A., Pothayee, N., Seleem, M. N., Tyler, R. D., Jr, Brenseke, B., Srinaganathan, N., et al. (2009). Antibacterial Efficacy of Core-Shell Nanostructures Encapsulating Gentamicin against an In Vivo Intracellular Salmonella Model. Int. J. Nanomedicine 4, 289–297. doi:10.2147/ijn.s7137

Schifferers, R. M., Storm, G., and Bakker-Woudenberg, I. A. M. (2001). Host Factors Influencing the Preferential Localization of Sterically Stabilized Liposomes in Klebsiella Pneumoniae-Infected Rat Lung Tissue. Pharm. Res. 18, 780–787. doi:10.1023/A:1011088011226

Shi, S., Wu, S., Shen, Y., Zhang, S., Xiao, Y., He, X., et al. (2018). Iron Oxide Nanorzyme Suppresses Intracellular Salmonella Enteritis: Growth and Alleviates Infection In Vivo. Theranostics 8, 6149–6162. doi:10.7150/thno.29030

Shima, K., Coopmeiners, J., Graupeunter, S., Dalhoff, K., and Rupp, J. (2016). Impact of Micro-Environmental Changes on Respiratory Tract Infections with Intracellular Bacteria. FEBS Lett. 590, 3857–3904. doi:10.1002/1873-3468.12353

Singh, R., Patil, S., Singh, N., and Gupta, S. (2017). Dual Functionality Nanobioconjugates Targeting Intracellular Bacteria in Cancer Cells with Enhanced Antimicrobial Activity. Sci. Rep. 7, 5792. doi:10.1038/s41598-017-06014-4

Subbaihodoss, G., Shariiff, S., Grijpma, D. W., Laurent, S., van der Mei, H. C., Mahmoudi, M., et al. (2012). Magnetic Targeting of Surface-Modified Superparamagnetic Iron Oxide Nanoparticles Yields Antibacterial Efficacy against Biofilms of Gentamicin-Resistant Staphylococci. Acta Biomater. 8, 2047–2055. doi:10.1016/j.actbio.2012.03.002

Subramaniam, S., Thomas, N., Gustafsson, H., Jambhrunkar, M., Kidd, S. P., and Prestidge, C. A. (2019). Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections. Antibiotics 8, 39. doi:10.3390/antibiotics8020039

Wang, Z., Mei, L., Liu, X., and Zhou, Q. (2021). Hierarchically Hybrid Biocoatings on Ti Implants for Enhanced Antibacterial Activity and Osteogenesis. Colloids Surf. B: Biointerfaces 204, 111802. doi:10.1016/j.colsurfb.2021.111802

Wright, G. (2005). Bacterial Resistance to Antibiotics: Enzymatic Degradation and Modification. Adv. Drug Deliv. Rev. 57, 1451–1470. doi:10.1016/j.addr.2004.05.002

Xiao, K., Li, Y., Luo, J., Lee, J. S., Xiao, W., Gonik, A. M., et al. (2011). The Effect of Surface Charge on In Vivo Biodistribution of PEG-Oligocholic Acid Based Micellar Nanoparticles. Biomaterials 32, 3435–3446. doi:10.1016/j.biomaterials.2011.01.021

Yang, L., Han, D., Zhan, Q., Li, X., Shan, P., Hu, Y., et al. (2019). Blood TfR+ Exosomes Separated by a pH-Responsive Method Deliver Chemotherapeutics for Tumor Therapy. Theranostics 9, 7680–7696. doi:10.7150/thno.37220

Yang, P., Yang, S., Sun, P., Tian, Y., Gao, F., Wang, C., et al. (2021). fll Spectrin (SPTBN1): Biological Function and Clinical Potential in Cancer and Other Diseases. Int. J. Biol. Sci. 17, 32–49. doi:10.7150/ijbs.52375

Zhu, Y., Liu, L., Sun, Z., Ji, Y., Wang, D., Mei, L., et al. (2021). Fucoidan as a Marine-Targeting Nanoparticle with Microenvironment-Responsive Antibiotic Release to Eliminate Intracellular Staphylococcus A and Associated Infection. ACS Appl. Mater. Inter. 10, 14299–14311. doi:10.1021/acsamat20200355

Yu, Z., Li, Q., Wang, J., Yu, Y., Wang, Y., Zhou, Q., et al. (2020). Reactive Oxygen Species-Related Nanoparticle Toxicity in the Biomedical Field. Nanoscale Res. Lett. 15, 1–14. doi:10.1186/s11671-020-03344-7

Zheng, W., Hao, Y., Wang, D., Huang, H., Guo, F., Sun, Z., et al. (2021). Preparation of Triamcinolone Acetonide-Loaded Chitosan/Fucoidan Hydrogel and its Potential Application as an Oral Mucosa Patch. Carbohydr. Polym. 272, 118493. doi:10.1016/j.carbpol.2021.118493

Zhu, Y., Liu, L., Sun, Z., Ji, Y., Wang, D., Mei, L., et al. (2021). Fucoidan as a Marine-Origin Prebiotic Modulates the Growth and Antibacterial Ability of Lactobacillus Rhamnosus. Int. J. Biol. Macromolecules 180, 599–607. doi:10.1016/j.ijbiomac.2021.03.065

Zong, T., Yang, Y., Zhao, H., Li, L., Liu, M., Fu, X., et al. (2021). tsRNAAs: Novel Small Molecules from Cell Function and Regulatory Mechanism to Therapeutic Targets. Cell Prolif 54, e12977. doi:10.1111/cpr.12977

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qi, Shan, Wang, Li, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.